Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Go back to Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma| Merck & Co. (NYSE: MRK) | Delayed: 149.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $65.46 | |||
| Open | $149.50 | 52 Week Low | $47.97 | |||
| Day High | $149.50 | P/E | 101.70 | |||
| Day Low | $149.50 | EPS | $1.47 | |||
| Volume | 13,707 | |||||
